---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Limitations of current therapies"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Limitations of current therapies. Topics: Positive airway pressure nonadherence across studies, Long-term adoption of positive airway pressure in the VA/DoD 2025 guideline, Cardiovascular outcomes with positive airway pressure: SAVE trial, Cardiovascular outcomes with positive airway pressure: meta-analysis of randomized trials, and 5 further topics. 10 evidence topics quoted from 22 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Limitations of current therapies

<a id="heading-2.2.2.1.8"></a>

## 2.2.2.1.8 Limitations of Current Therapies

<a id="topic-2.2.2.1.8-1"></a>

### Summary

- PAP nonadherence, by definition: with adherence defined as more than 4 hours of nightly use, 46% to 83% of people with OSA have been reported to be nonadherent (Weaver and Grunstein 2008). Relative to a 7-hour night, the overall CPAP non-adherence rate across 20 years of studies was 34.1%, with no significant improvement over that period (Rotenberg et al. 2016). By the CMS definition (at least 4 hours of use on 70% of nights in a consecutive 30-day period within the first 90 days), the observed 90-day adherence rate was 75% (Cistulli et al. 2019), which also cites prior studies in which up to 24% of patients may not fulfill their PAP prescription. The VA/DoD 2025 guideline states that as many as half of patients prescribed PAP have been unable to adopt it long-term. Mean adherence in the CPAP groups of two cardiovascular outcome trials was 3.3 hours per night (McEvoy et al. 2016) and 2.78 hours per night (Sánchez-de-la-Torre et al. 2020).
- PAP termination and persistence: in claims data, with termination defined as cessation of CPAP reimbursements, termination rates among 480,000 people were 23.1%, 37.1%, and 47.7% after 1, 2, and 3 years (Pépin et al. 2021); a second analysis of 174,270 individuals reported a 1-year termination rate of 22.3% (Bailly et al. 2024). Under telemonitoring (95.7% of 84,550 people), PAP persistence was 83.5% at 1 year, 68.4% at 3 years, and 60.5% at 5 years, and issues with PAP treatment accounted for 54.9% of documented reasons for stopping (Baillieul et al. 2026).
- Cardiovascular outcomes: CPAP did not reduce cardiovascular events in randomized trials. In one trial (McEvoy et al. 2016), a primary end-point event occurred in 17.0% of the CPAP group and 15.4% of the usual-care group after a mean 3.7 years (hazard ratio 1.10; 95% CI 0.91 to 1.32). Cardiovascular events occurred in 16% vs 17% in a second trial (Sánchez-de-la-Torre et al. 2020; hazard ratio 0.89; 95% CI 0.68 to 1.17), and the primary endpoint in 18.1% vs 22.1% in a third (Peker et al. 2016; hazard ratio 0.80; 95% CI 0.46 to 1.41). A meta-analysis of 10 randomized trials (7266 participants) found a relative risk of 0.77 (95% CI 0.53 to 1.13) for a composite of acute coronary syndrome, stroke, or vascular death. An individual participant data meta-analysis (4186 participants) found a hazard ratio of 1.01 (95% CI 0.87 to 1.17) for the first major adverse cardiac or cerebrovascular event, and 0.69 (95% CI 0.52 to 0.92) with good adherence in an on-treatment analysis. The AASM guideline finds insufficient and inconclusive evidence to recommend or withhold PAP in non-sleepy adults to reduce cardiovascular events or mortality.
- Oral appliances: in pooled trials (hypopnea scoring rule not stated), the mean AHI reduction was 6.24 events/h greater with CPAP than with oral appliances, and the odds of reaching the target AHI in moderate to severe OSA were greater with CPAP; no randomized trial has compared objective oral appliance adherence with CPAP (AASM and AADSM guideline). The ERS guideline suggests CPAP over mandibular advancement devices (conditional recommendation, very low quality of evidence) and regards the two as equal in mild to moderate OSA.
- Positional therapy: guideline recommendations apply to positional OSA (VA/DoD, weak for) and to mild or moderate position-dependent OSA with a nonsupine AHI below 15 events/h (ERS). In a review of 8 studies (323 participants; hypopnea scoring rule not stated), CPAP reduced the AHI by 6.4 events per hour more than positional therapy (2 studies), all studies were of short duration, and long-term effects could not be assessed. The VA/DoD guideline states that positional therapy was not associated with improved functional outcomes or quality of life, with very low confidence in the evidence.
- Hypoglossal nerve stimulation: the FDA device criteria summarized by the VA/DoD guideline include moderate to severe OSA with an AHI of 15 to 100 events per hour and failure of or intolerance to PAP. The ERS guideline suggests against its use as first-line treatment and suggests it as salvage treatment for patients with an AHI below 50 events/h and a BMI below 32 kg/m2; its trials included about 10% of screened patients. In one randomized trial cited by the VA/DoD guideline, 72.5% of 138 participants experienced a total of 164 procedure- or study-related adverse events. Apnimed cites invasiveness, cost, and BMI and airway collapse pattern exclusions, and states that approximately 100,000 patients had received the therapy as of March 2025.
- Tirzepatide: its OSA indication is limited to moderate to severe OSA in adults with obesity, with a reduced-calorie diet and increased physical activity; its OSA trials enrolled adults with an AHI of at least 15 and a BMI of at least 30 kg/m2. The AASM fact sheet states that there is no head-to-head evidence comparing it with other OSA treatments.
- Wake-promoting agents: the solriamfetol and armodafinil labels indicate them to improve wakefulness in OSA and state that neither treats the underlying airway obstruction.

Source: [Weaver and Grunstein (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2645251/); [Rotenberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4992257/); [Cistulli et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6589354/); [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf); [McEvoy et al. (2016)](https://www.nejm.org/doi/full/10.1056/NEJMoa1606599); [Sánchez-de-la-Torre et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31839558/); [Pépin et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7957656/); [Bailly et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12039934/); [Baillieul et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43033026/); [Peker et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26914592/); [Yu et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5541330/); [Sánchez-de-la-Torre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10548300/); [Patil et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374094/); [Ramar et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481062/); [Randerath et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9489103/); [Srijithesh et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6491901/); [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm); [Eli Lilly Zepbound prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf); [American Academy of Sleep Medicine Zepbound provider fact sheet (2026)](https://aasm.org/wp-content/uploads/2026/04/ProviderFS_Zepbound_2026-DIGITAL-2.pdf); [Axsome Sunosi prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211230s009lbl.pdf); [Teva Nuvigil prescribing information (2017)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021875s023lbl.pdf)

<a id="topic-2.2.2.1.8-2"></a>

### Positive airway pressure nonadherence across studies

> “When adherence is defined as greater than 4 hours of nightly use, 46 to 83% of patients with obstructive sleep apnea have been reported to be nonadherent to treatment.”

Source: [Weaver and Grunstein (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2645251/)

> “The overall CPAP non-adherence rate based on a 7-h/night sleep time that was reported in studies conducted over the twenty year time frame was 34.1 %. There was no significant improvement over the time frame.”

Source: [Rotenberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4992257/)

<a id="topic-2.2.2.1.8-3"></a>

### Long-term adoption of positive airway pressure in the VA/DoD 2025 guideline

> “As many as half of patients prescribed positive airway pressure (PAP) therapy for the treatment of OSA have been unable to adopt PAP therapy long-term.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.8-4"></a>

### Cardiovascular outcomes with positive airway pressure: SAVE trial

> “In the CPAP group, the mean duration of adherence to CPAP therapy was 3.3 hours per night, and the mean apnea–hypopnea index (the number of apnea or hypopnea events per hour of recording) decreased from 29.0 events per hour at baseline to 3.7 events per hour during follow-up.”
> “Therapy with CPAP plus usual care, as compared with usual care alone, did not prevent cardiovascular events in patients with moderate-to-severe obstructive sleep apnea and established cardiovascular disease.”

Source: [McEvoy et al. (2016)](https://www.nejm.org/doi/full/10.1056/NEJMoa1606599)

<a id="topic-2.2.2.1.8-5"></a>

### Cardiovascular outcomes with positive airway pressure: meta-analysis of randomized trials

> “In this meta-analysis of 10 randomized clinical trials including 7266 patients, there was no significant association of PAP compared with no treatment (or sham PAP) on a composite outcome of acute coronary syndrome events, stroke, or vascular death (relative risk, 0.77 [95% CI, 0.53-1.13]). There was also no significant association with individual outcomes or all-cause death.”

Source: [Yu et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5541330/)

<a id="topic-2.2.2.1.8-6"></a>

### Insufficient evidence for positive airway pressure to reduce cardiovascular events in non-sleepy adults

> “There is insufficient and inconclusive evidence to either recommend or withhold PAP to treat non-sleepy adults with OSA as a means to reduce cardiovascular events or mortality.”

Source: [Patil et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374094/)

<a id="topic-2.2.2.1.8-7"></a>

### Eligibility limits of hypoglossal nerve stimulation and surgery

> “The invasiveness of both the diagnostic testing and implantation procedure, the high cost of the procedure, and exclusions of patients with BMI above a certain threshold or with an upper airway collapse pattern that are not amenable to treatment with the device, can be a deterrent to”
> “These procedures are invasive and painful and can have complications such as nerve damage or swallowing difficulties.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.2.1.8-8"></a>

### Wake-promoting agents do not treat airway obstruction

> “These drugs can help OSA patients stay more awake during the day but do not treat the underlying disease or alleviate night-time breathing disruption and hypoxemia that is linked to cardiovascular risk.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.2.1.8-9"></a>

### No pharmacotherapy approved for OSA without obesity before tirzepatide, manufacturer statement

> “Prescription drug development in the field of OSA is relatively novel, and until the approval of tirzepatide in 2024 for moderate to severe OSA in obese adults in combination with a reduced-calorie diet and increased physical activity, the FDA historically did not have well-established therapeutic endpoints for this indication.”
> “While weight loss treatments have broad appeal, they are not clinically relevant for the majority of OSA patients, as most lack a distinct approval in OSA and tirzepatide’s approved indication is limited to only those individuals with moderate-severe OSA and a comorbid diagnosis of obesity.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.2.1.8-10"></a>

### Limited applicability of current alternatives in an editorial on SynAIRgy

> “Alternative interventions, such as oral appliances, hypoglossal nerve stimulation, and weight loss strategies, including pharmacologic approaches such as tirzepatide in selected patients with obesity, have expanded the range of available therapies. However, these approaches are not universally applicable, and many patients remain untreated or inadequately treated.”

Source: [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
